Prostate Cancer Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
Prostate Cancer Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Prostate Cancer Drugs worldwide, with company and product introduction, position in the Prostate Cancer Drugs market
Market status and development trend of Prostate Cancer Drugs by types and applications
Cost and profit status of Prostate Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Prostate Cancer Drugs market as:
Global Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Prostate Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Global Prostate Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinics
Hospitals
Other
Global Prostate Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Prostate Cancer Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Prostate Cancer Drugs worldwide, with company and product introduction, position in the Prostate Cancer Drugs market
Market status and development trend of Prostate Cancer Drugs by types and applications
Cost and profit status of Prostate Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Prostate Cancer Drugs market as:
Global Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Prostate Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Global Prostate Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinics
Hospitals
Other
Global Prostate Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PROSTATE CANCER DRUGS
1.1 Definition of Prostate Cancer Drugs in This Report
1.2 Commercial Types of Prostate Cancer Drugs
1.2.1 Hormonal Therapy
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.3 Downstream Application of Prostate Cancer Drugs
1.3.1 Clinics
1.3.2 Hospitals
1.3.3 Other
1.4 Development History of Prostate Cancer Drugs
1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
1.5.1 Global Prostate Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Prostate Cancer Drugs 2013-2017
2.2 Production Market of Prostate Cancer Drugs by Regions
2.2.1 Production Volume of Prostate Cancer Drugs by Regions
2.2.2 Production Value of Prostate Cancer Drugs by Regions
2.3 Demand Market of Prostate Cancer Drugs by Regions
2.4 Production and Demand Status of Prostate Cancer Drugs by Regions
2.4.1 Production and Demand Status of Prostate Cancer Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Prostate Cancer Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Prostate Cancer Drugs by Types
3.2 Production Value of Prostate Cancer Drugs by Types
3.3 Market Forecast of Prostate Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Prostate Cancer Drugs by Downstream Industry
4.2 Market Forecast of Prostate Cancer Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Prostate Cancer Drugs by Major Manufacturers
6.2 Production Value of Prostate Cancer Drugs by Major Manufacturers
6.3 Basic Information of Prostate Cancer Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie
7.1.1 Company profile
7.1.2 Representative Prostate Cancer Drugs Product
7.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.2 Astellas Pharma
7.2.1 Company profile
7.2.2 Representative Prostate Cancer Drugs Product
7.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
7.3 Astra Zeneca
7.3.1 Company profile
7.3.2 Representative Prostate Cancer Drugs Product
7.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca
7.4 Johnson & Johnson
7.4.1 Company profile
7.4.2 Representative Prostate Cancer Drugs Product
7.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.5 Sanofi
7.5.1 Company profile
7.5.2 Representative Prostate Cancer Drugs Product
7.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.6 GlaxoSmithKline
7.6.1 Company profile
7.6.2 Representative Prostate Cancer Drugs Product
7.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.7 Merck Group
7.7.1 Company profile
7.7.2 Representative Prostate Cancer Drugs Product
7.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group
7.8 Novartis
7.8.1 Company profile
7.8.2 Representative Prostate Cancer Drugs Product
7.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.9 Amgen
7.9.1 Company profile
7.9.2 Representative Prostate Cancer Drugs Product
7.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
7.10 Bayer HealthCare
7.10.1 Company profile
7.10.2 Representative Prostate Cancer Drugs Product
7.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.11 Ferring Pharmaceutical
7.11.1 Company profile
7.11.2 Representative Prostate Cancer Drugs Product
7.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceutical
7.12 Janssen Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Prostate Cancer Drugs Product
7.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen Pharmaceuticals
7.13 Endo Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Prostate Cancer Drugs Product
7.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
7.14 BMS
7.14.1 Company profile
7.14.2 Representative Prostate Cancer Drugs Product
7.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS
7.15 Takeda Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative Prostate Cancer Drugs Product
7.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
7.16 Northwest Biotherapeutics
7.17 Teva Pharmaceutical
7.18 Boehringer Ingelheim
7.19 Foresee Pharmaceuticals
7.20 Tokai Pharmaceuticals
7.21 Spectrum Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS
8.1 Industry Chain of Prostate Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS
9.1 Cost Structure Analysis of Prostate Cancer Drugs
9.2 Raw Materials Cost Analysis of Prostate Cancer Drugs
9.3 Labor Cost Analysis of Prostate Cancer Drugs
9.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROSTATE CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Prostate Cancer Drugs in This Report
1.2 Commercial Types of Prostate Cancer Drugs
1.2.1 Hormonal Therapy
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.3 Downstream Application of Prostate Cancer Drugs
1.3.1 Clinics
1.3.2 Hospitals
1.3.3 Other
1.4 Development History of Prostate Cancer Drugs
1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
1.5.1 Global Prostate Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Prostate Cancer Drugs 2013-2017
2.2 Production Market of Prostate Cancer Drugs by Regions
2.2.1 Production Volume of Prostate Cancer Drugs by Regions
2.2.2 Production Value of Prostate Cancer Drugs by Regions
2.3 Demand Market of Prostate Cancer Drugs by Regions
2.4 Production and Demand Status of Prostate Cancer Drugs by Regions
2.4.1 Production and Demand Status of Prostate Cancer Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Prostate Cancer Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Prostate Cancer Drugs by Types
3.2 Production Value of Prostate Cancer Drugs by Types
3.3 Market Forecast of Prostate Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Prostate Cancer Drugs by Downstream Industry
4.2 Market Forecast of Prostate Cancer Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Prostate Cancer Drugs by Major Manufacturers
6.2 Production Value of Prostate Cancer Drugs by Major Manufacturers
6.3 Basic Information of Prostate Cancer Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie
7.1.1 Company profile
7.1.2 Representative Prostate Cancer Drugs Product
7.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.2 Astellas Pharma
7.2.1 Company profile
7.2.2 Representative Prostate Cancer Drugs Product
7.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
7.3 Astra Zeneca
7.3.1 Company profile
7.3.2 Representative Prostate Cancer Drugs Product
7.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca
7.4 Johnson & Johnson
7.4.1 Company profile
7.4.2 Representative Prostate Cancer Drugs Product
7.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.5 Sanofi
7.5.1 Company profile
7.5.2 Representative Prostate Cancer Drugs Product
7.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.6 GlaxoSmithKline
7.6.1 Company profile
7.6.2 Representative Prostate Cancer Drugs Product
7.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.7 Merck Group
7.7.1 Company profile
7.7.2 Representative Prostate Cancer Drugs Product
7.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group
7.8 Novartis
7.8.1 Company profile
7.8.2 Representative Prostate Cancer Drugs Product
7.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.9 Amgen
7.9.1 Company profile
7.9.2 Representative Prostate Cancer Drugs Product
7.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
7.10 Bayer HealthCare
7.10.1 Company profile
7.10.2 Representative Prostate Cancer Drugs Product
7.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.11 Ferring Pharmaceutical
7.11.1 Company profile
7.11.2 Representative Prostate Cancer Drugs Product
7.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceutical
7.12 Janssen Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Prostate Cancer Drugs Product
7.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen Pharmaceuticals
7.13 Endo Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Prostate Cancer Drugs Product
7.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
7.14 BMS
7.14.1 Company profile
7.14.2 Representative Prostate Cancer Drugs Product
7.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS
7.15 Takeda Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative Prostate Cancer Drugs Product
7.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
7.16 Northwest Biotherapeutics
7.17 Teva Pharmaceutical
7.18 Boehringer Ingelheim
7.19 Foresee Pharmaceuticals
7.20 Tokai Pharmaceuticals
7.21 Spectrum Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS
8.1 Industry Chain of Prostate Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS
9.1 Cost Structure Analysis of Prostate Cancer Drugs
9.2 Raw Materials Cost Analysis of Prostate Cancer Drugs
9.3 Labor Cost Analysis of Prostate Cancer Drugs
9.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROSTATE CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
